Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments
- November 2017 •
- 47 pages •
- Report ID: 5289060
Hypertrophic scars therapeutics pipeline in 2017
Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.
Insights on pipeline segments
Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream’s safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.
Specific targeted therapy expected to create opportunities for the pharmaceutical companies
The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.
Technological advancements enhancing the Pipeline Growth
Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.
Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.
Hypertrophic Scars Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company